Insider Trades105 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 226 | $26.28 | $3.4B | -33.31% | +52.77% | $5.9K | -0.15% | 10b5-1 | Stalk |
| Aug 13, 2026 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 1,556 | $26.28 | $3.4B | -33.31% | +52.77% | $40.9K | -0.92% | 10b5-1 | Stalk |
| Aug 13, 2026 | Sell | DYN | Erick Lucera | Chief Financial Officer | 1,797 | $26.28 | $3.4B | -33.31% | +52.77% | $47.2K | -1.48% | 10b5-1 | Stalk |
| Aug 13, 2026 | Sell | DYN | John Cox | CEO & President | 4,986 | $26.28 | $3.4B | -33.31% | +52.77% | $131.0K | -1.35% | 10b5-1 | Stalk |
| Jun 25, 2026 | Sell | DYN | Erick Lucera | Chief Financial Officer | 2,362 | $20.37 | $3.4B | -33.31% | +52.77% | $48.1K | -1.91% | — | Stalk |
| Jun 16, 2026 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 145 | $18.33 | $3.4B | -33.31% | +52.77% | $2.7K | -0.09% | 10b5-1 | Stalk |
| Jun 16, 2026 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 887 | $18.33 | $3.4B | -33.31% | +52.77% | $16.3K | -0.52% | 10b5-1 | Stalk |
| Jun 16, 2026 | Sell | DYN | John Cox | CEO & President | 2,683 | $18.33 | $3.4B | -33.31% | +52.77% | $49.2K | -0.72% | 10b5-1 | Stalk |
| May 13, 2026 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 228 | $18.36 | $3.4B | -33.31% | +52.77% | $4.2K | -0.15% | 10b5-1 | Stalk |
| May 13, 2026 | Sell | DYN | Erick Lucera | Chief Financial Officer | 1,448 | $18.36 | $3.4B | -33.31% | +52.77% | $26.6K | -1.15% | 10b5-1 | Stalk |
| May 13, 2026 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 1,564 | $18.36 | $3.4B | -33.31% | +52.77% | $28.7K | -0.91% | 10b5-1 | Stalk |
| May 13, 2026 | Sell | DYN | John Cox | CEO & President | 3,311 | $18.36 | $3.4B | -33.31% | +52.77% | $60.8K | -0.88% | 10b5-1 | Stalk |
| Apr 1, 2026 | Sell | DYN | Erick Lucera | Chief Financial Officer | 5,727 | $18.64 | $3.4B | -33.31% | +52.77% | $106.8K | -4.37% | 10b5-1 | Stalk |
| Mar 5, 2026 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 148 | $14.90 | $3.4B | -33.31% | +52.77% | $2.2K | -0.10% | 10b5-1 | Stalk |
| Mar 5, 2026 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 904 | $14.90 | $3.4B | -33.31% | +52.77% | $13.5K | -0.52% | 10b5-1 | Stalk |
| Mar 5, 2026 | Sell | DYN | John Cox | CEO & President | 2,732 | $14.90 | $3.4B | -33.31% | +52.77% | $40.7K | -0.72% | 10b5-1 | Stalk |
| Dec 5, 2025 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 144 | $20.72 | $3.4B | -33.31% | +52.77% | $3.0K | -0.15% | 10b5-1 | Stalk |
| Dec 5, 2025 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 880 | $20.72 | $3.4B | -33.31% | +52.77% | $18.2K | -1.00% | 10b5-1 | Stalk |
| Dec 5, 2025 | Sell | DYN | John Cox | CEO & President | 2,662 | $20.72 | $3.4B | -33.31% | +52.77% | $55.2K | -1.33% | 10b5-1 | Stalk |
| Sep 5, 2025 | Sell | DYN | John Cox | CEO & President | 2,640 | $13.41 | $3.4B | -33.31% | +52.77% | $35.4K | -1.31% | 10b5-1 | Stalk |
| Sep 4, 2025 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 1,038 | $13.29 | $3.4B | -33.31% | +52.77% | $13.8K | -0.54% | 10b5-1 | Stalk |
| Sep 4, 2025 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 4,425 | $13.30 | $3.4B | -33.31% | +52.77% | $58.8K | -2.43% | 10b5-1 | Stalk |
| Jul 14, 2025 | Buy | DYN | John Cox | CEO & President | 140,000 | $6.51 | $3.4B | -33.31% | +52.77% | $911.0K | +5.71% | — | Stalk |
| Jun 5, 2025 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 146 | $13.35 | $3.4B | -33.31% | +52.77% | $1.9K | -0.15% | 10b5-1 | Stalk |
| Jun 5, 2025 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 1,342 | $13.35 | $3.4B | -33.31% | +52.77% | $17.9K | -1.43% | 10b5-1 | Stalk |
| Jun 5, 2025 | Sell | DYN | John Cox | CEO & President | 4,060 | $13.35 | $3.4B | -33.31% | +52.77% | $54.2K | -2.78% | 10b5-1 | Stalk |
| Mar 13, 2025 | Sell | DYN | Johanna Friedl-Naderer | Chief Commercial Officer | 143 | $12.12 | $3.4B | -33.31% | +52.77% | $1.7K | -0.15% | 10b5-1 | Stalk |
| Mar 11, 2025 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 1,343 | $11.38 | $3.4B | -33.31% | +52.77% | $15.3K | -1.09% | 10b5-1 | Stalk |
| Mar 11, 2025 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,153 | $11.38 | $3.4B | -33.31% | +52.77% | $24.5K | -1.09% | 10b5-1 | Stalk |
| Mar 5, 2025 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 917 | $11.83 | $3.4B | -33.31% | +52.77% | $10.8K | -0.74% | 10b5-1 | Stalk |
| Mar 5, 2025 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 1,094 | $11.83 | $3.4B | -33.31% | +52.77% | $12.9K | -0.55% | 10b5-1 | Stalk |
| Mar 5, 2025 | Sell | DYN | Douglas Kerr | Chief Medical Officer | 1,343 | $11.83 | $3.4B | -33.31% | +52.77% | $15.9K | -1.41% | 10b5-1 | Stalk |
| Mar 5, 2025 | Sell | DYN | John Cox | CEO & President | 4,061 | $11.83 | $3.4B | -33.31% | +52.77% | $48.0K | -2.70% | 10b5-1 | Stalk |
| Feb 18, 2025 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 2,488 | $13.95 | $3.4B | -33.31% | +52.77% | $34.7K | -1.96% | 10b5-1 | Stalk |
| Feb 18, 2025 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,598 | $13.95 | $3.4B | -33.31% | +52.77% | $36.2K | -1.29% | 10b5-1 | Stalk |
| Dec 11, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 1,455 | $28.12 | $3.4B | -33.31% | +52.77% | $40.9K | -1.13% | 10b5-1 | Stalk |
| Dec 11, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,334 | $28.12 | $3.4B | -33.31% | +52.77% | $65.6K | -1.14% | 10b5-1 | Stalk |
| Nov 18, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 2,735 | $28.20 | $3.4B | -33.31% | +52.77% | $77.1K | -2.77% | 10b5-1 | Stalk |
| Nov 18, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,856 | $28.20 | $3.4B | -33.31% | +52.77% | $80.5K | -2.03% | 10b5-1 | Stalk |
| Sep 18, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 1,390 | $34.55 | $3.4B | -33.31% | +52.77% | $48.0K | -1.39% | 10b5-1 | Stalk |
| Sep 18, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,339 | $34.55 | $3.4B | -33.31% | +52.77% | $80.8K | -1.64% | 10b5-1 | Stalk |
| Sep 18, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 8,976 | $34.41 | $3.4B | -33.31% | +52.77% | $308.9K | -3.24% | 10b5-1 | Stalk |
| Sep 11, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 1,468 | $31.89 | $3.4B | -33.31% | +52.77% | $46.8K | -1.45% | 10b5-1 | Stalk |
| Sep 11, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,161 | $31.89 | $3.4B | -33.31% | +52.77% | $68.9K | -1.49% | 10b5-1 | Stalk |
| Sep 11, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 5,270 | $31.89 | $3.4B | -33.31% | +52.77% | $168.1K | -1.82% | 10b5-1 | Stalk |
| Sep 6, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 242,552 | $22.74 | $3.4B | -33.31% | +52.77% | $5.5M | -0.63% | — | Stalk |
| Sep 4, 2024 | Buy | DYN | John Cox | CEO & President | 32,000 | $33.04 | $3.4B | -33.31% | +52.77% | $1.1M | +1000.00% | — | Stalk |
| Aug 19, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 2,321 | $45.12 | $3.4B | -33.31% | +52.77% | $104.7K | -0.80% | 10b5-1 | Stalk |
| Aug 19, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,636 | $45.12 | $3.4B | -33.31% | +52.77% | $118.9K | -0.90% | 10b5-1 | Stalk |
| Aug 19, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 2,705 | $45.12 | $3.4B | -33.31% | +52.77% | $122.1K | -1.01% | 10b5-1 | Stalk |
| Aug 19, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 2,752 | $45.12 | $3.4B | -33.31% | +52.77% | $124.2K | -1.22% | 10b5-1 | Stalk |
| Aug 19, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 2,910 | $45.12 | $3.4B | -33.31% | +52.77% | $131.3K | -0.99% | 10b5-1 | Stalk |
| Jun 21, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 79,900 | $20.32 | $3.4B | -33.31% | +52.77% | $1.6M | +0.00% | 10b5-1 | Stalk |
| Jun 21, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 80,000 | $20.32 | $3.4B | -33.31% | +52.77% | $1.6M | +0.00% | 10b5-1 | Stalk |
| Jun 12, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 80,000 | $19.45 | $3.4B | -33.31% | +52.77% | $1.6M | +0.00% | 10b5-1 | Stalk |
| Jun 11, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 1,823 | $31.34 | $3.4B | -33.31% | +52.77% | $57.1K | -1.33% | 10b5-1 | Stalk |
| Jun 11, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,136 | $31.34 | $3.4B | -33.31% | +52.77% | $66.9K | -1.43% | 10b5-1 | Stalk |
| Jun 11, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 2,636 | $31.27 | $3.4B | -33.31% | +52.77% | $82.4K | -0.89% | 10b5-1 | Stalk |
| Jun 10, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 2,921 | $30.74 | $3.4B | -33.31% | +52.77% | $89.8K | -1.26% | 10b5-1 | Stalk |
| Jun 10, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 165,270 | $18.32 | $3.4B | -33.31% | +52.77% | $3.0M | -0.63% | 10b5-1 | Stalk |
| May 20, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 60,852 | $16.99 | $3.4B | -33.31% | +52.77% | $1.0M | +0.00% | 10b5-1 | Stalk |
| May 16, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 2,381 | $28.27 | $3.4B | -33.31% | +52.77% | $67.3K | -0.80% | — | Stalk |
| May 16, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 2,588 | $28.27 | $3.4B | -33.31% | +52.77% | $73.2K | -1.09% | — | Stalk |
| May 16, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,705 | $28.27 | $3.4B | -33.31% | +52.77% | $76.5K | -0.89% | — | Stalk |
| May 16, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 2,738 | $28.27 | $3.4B | -33.31% | +52.77% | $77.4K | -0.88% | — | Stalk |
| May 16, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 2,774 | $28.27 | $3.4B | -33.31% | +52.77% | $78.4K | -1.00% | — | Stalk |
| Mar 11, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,081 | $25.70 | $3.4B | -33.31% | +52.77% | $53.5K | -1.35% | — | Stalk |
| Mar 11, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 2,615 | $25.65 | $3.4B | -33.31% | +52.77% | $67.1K | -0.86% | — | Stalk |
| Mar 8, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 29,491 | $26.59 | $3.4B | -33.31% | +52.77% | $784.2K | -5.84% | — | Stalk |
| Mar 8, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 175,176 | $16.02 | $3.4B | -33.31% | +52.77% | $2.8M | -0.25% | — | Stalk |
| Mar 8, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 217,426 | $15.91 | $3.4B | -33.31% | +52.77% | $3.5M | -0.13% | — | Stalk |
| Mar 8, 2024 | Sell | DYN | Joshua T Brumm | CEO & President | 843,073 | $15.91 | $3.4B | -33.31% | +52.77% | $13.4M | -0.25% | — | Stalk |
| Mar 7, 2024 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 1,591 | $25.85 | $3.4B | -33.31% | +52.77% | $41.1K | -0.85% | — | Stalk |
| Mar 7, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 2,273 | $25.85 | $3.4B | -33.31% | +52.77% | $58.8K | -1.83% | — | Stalk |
| Mar 7, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 2,373 | $25.85 | $3.4B | -33.31% | +52.77% | $61.3K | -1.51% | — | Stalk |
| Mar 7, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 2,434 | $25.85 | $3.4B | -33.31% | +52.77% | $62.9K | -1.69% | — | Stalk |
| Mar 7, 2024 | Sell | DYN | Joshua T Brumm | CEO & President | 9,086 | $25.85 | $3.4B | -33.31% | +52.77% | $234.9K | -1.61% | — | Stalk |
| Mar 7, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 9,921 | $25.86 | $3.4B | -33.31% | +52.77% | $256.6K | -3.12% | 10b5-1 | Stalk |
| Feb 29, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 25,480 | $14.54 | $3.4B | -33.31% | +52.77% | $370.4K | +0.00% | 10b5-1 | Stalk |
| Feb 29, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 57,056 | $14.59 | $3.4B | -33.31% | +52.77% | $832.7K | +0.00% | 10b5-1 | Stalk |
| Feb 29, 2024 | Sell | DYN | Joshua T Brumm | CEO & President | 200,000 | $17.25 | $3.4B | -33.31% | +52.77% | $3.4M | +0.00% | 10b5-1 | Stalk |
| Feb 28, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 407 | $25.00 | $3.4B | -33.31% | +52.77% | $10.2K | -0.25% | 10b5-1 | Stalk |
| Feb 12, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 5,493 | $25.07 | $3.4B | -33.31% | +52.77% | $137.7K | -3.25% | 10b5-1 | Stalk |
| Jan 29, 2024 | Sell | DYN | Joshua T Brumm | CEO & President | 21,500 | $20.90 | $3.4B | -33.31% | +52.77% | $449.3K | -1.87% | — | Stalk |
| Jan 26, 2024 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 100 | $25.00 | $3.4B | -33.31% | +52.77% | $2.5K | -0.06% | 10b5-1 | Stalk |
| Jan 26, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 26,000 | $12.69 | $3.4B | -33.31% | +52.77% | $329.8K | +0.00% | 10b5-1 | Stalk |
| Jan 26, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 40,000 | $12.63 | $3.4B | -33.31% | +52.77% | $505.1K | +0.00% | 10b5-1 | Stalk |
| Jan 3, 2024 | Sell | DYN | Richard William Scalzo | SVP, Head of Finance & Admin. | 26,000 | $9.92 | $3.4B | -33.31% | +52.77% | $257.9K | +0.00% | 10b5-1 | Stalk |
| Jan 3, 2024 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 155,779 | $10.91 | $3.4B | -33.31% | +52.77% | $1.7M | -1.59% | 10b5-1 | Stalk |
| Jan 3, 2024 | Sell | DYN | Joshua T Brumm | CEO & President | 539,438 | $11.52 | $3.4B | -33.31% | +52.77% | $6.2M | +0.00% | 10b5-1 | Stalk |
| Jan 2, 2024 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 51,900 | $10.48 | $3.4B | -33.31% | +52.77% | $543.8K | -1.19% | 10b5-1 | Stalk |
| Dec 14, 2023 | Sell | DYN | Richard William Scalzo | — | 2,376 | $12.02 | $3.4B | -33.31% | +52.77% | $28.6K | -1.88% | 10b5-1 | Stalk |
| Dec 11, 2023 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 1,245 | $10.72 | $3.4B | -33.31% | +52.77% | $13.3K | -0.79% | — | Stalk |
| Dec 11, 2023 | Sell | DYN | Richard William Scalzo | — | 1,380 | $10.72 | $3.4B | -33.31% | +52.77% | $14.8K | -1.08% | — | Stalk |
| Dec 11, 2023 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 1,467 | $10.72 | $3.4B | -33.31% | +52.77% | $15.7K | -0.82% | — | Stalk |
| Dec 11, 2023 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 1,616 | $10.72 | $3.4B | -33.31% | +52.77% | $17.3K | -0.85% | — | Stalk |
| Dec 11, 2023 | Sell | DYN | Wildon Farwell | Chief Medical Officer | 2,666 | $10.66 | $3.4B | -33.31% | +52.77% | $28.4K | -0.78% | 10b5-1 | Stalk |
| Dec 11, 2023 | Sell | DYN | Joshua T Brumm | — | 7,585 | $10.72 | $3.4B | -33.31% | +52.77% | $81.3K | -1.28% | — | Stalk |
| Dec 4, 2023 | Sell | DYN | Richard William Scalzo | — | 2,553 | $12.01 | $3.4B | -33.31% | +52.77% | $30.7K | -0.98% | 10b5-1 | Stalk |
| Nov 2, 2023 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 9,939 | $7.40 | $3.4B | -33.31% | +52.77% | $73.5K | -9.51% | 10b5-1 | Stalk |
| Sep 18, 2023 | Sell | DYN | Jonathan Mcneill | Chief Business Officer | 1,261 | $9.41 | $3.4B | -33.31% | +52.77% | $11.9K | -2.04% | — | Stalk |
| Sep 18, 2023 | Sell | DYN | Richard William Scalzo | — | 1,290 | $9.41 | $3.4B | -33.31% | +52.77% | $12.1K | -3.07% | — | Stalk |
| Sep 18, 2023 | Sell | DYN | Oxana Beskrovnaya | Chief Scientific Officer | 1,436 | $9.41 | $3.4B | -33.31% | +52.77% | $13.5K | -1.67% | — | Stalk |
| Sep 18, 2023 | Sell | DYN | Susanna Gatti High | Chief Operating Officer | 2,672 | $9.41 | $3.4B | -33.31% | +52.77% | $25.1K | -2.49% | — | Stalk |
| Sep 18, 2023 | Sell | DYN | Joshua T Brumm | — | 12,032 | $9.41 | $3.4B | -33.31% | +52.77% | $113.2K | -4.90% | — | Stalk |